T Cells Engineered against a Native Antigen Can Surmount Immunologic and Physical Barriers to Treat Pancreatic Ductal Adenocarcinoma.
about
Genetics and biology of pancreatic ductal adenocarcinomaFOLFIRINOX and translational studies: Towards personalized therapy in pancreatic cancerCXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma.Obstructive Sleep Apnea and Pathological Characteristics of Resected Pancreatic Ductal Adenocarcinoma.Improving the reliability of peer-reviewed publications: We are all in it together.Genetically Engineered Mouse Models of Pancreatic Cancer: The KPC Model (LSL-Kras(G12D/+) ;LSL-Trp53(R172H/+) ;Pdx-1-Cre), Its Variants, and Their Application in Immuno-oncology Drug Discovery.CD40 Stimulation Obviates Innate Sensors and Drives T Cell Immunity in Cancer.Prognostic value, localization and correlation of PD-1/PD-L1, CD8 and FOXP3 with the desmoplastic stroma in pancreatic ductal adenocarcinoma.Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses.CTLA-4/CD80 pathway regulates T cell infiltration into pancreatic cancer.T cell optimization for the treatment of pancreatic cancer.Distinct patterns of cytolytic T-cell activation by different tumour cells revealed by Ca2+ signalling and granule mobilization.Chimeric antigen receptor-modified T cells for the treatment of solid tumors: Defining the challenges and next steps.Obstacles Posed by the Tumor Microenvironment to T cell Activity: A Case for Synergistic Therapies.CAR T-cell therapy for pancreatic cancer.Pharmacotherapeutic Management of Pancreatic Ductal Adenocarcinoma: Current and Emerging Concepts.Association of Distinct Mutational Signatures With Correlates of Increased Immune Activity in Pancreatic Ductal Adenocarcinoma.Tumor-associated fibrosis as a regulator of tumor immunity and response to immunotherapy.Exploiting the neoantigen landscape for immunotherapy of pancreatic ductal adenocarcinoma.PD-L1 blockade enhances response of pancreatic ductal adenocarcinoma to radiotherapy.Pancreatic Cancer: Current Progress and Future Challenges.Cancer vaccines and immunotherapeutic approaches in hepatobiliary and pancreatic cancers.Pancreatic Cancer Chemoresistance to Gemcitabine.Emerging trends in the immunotherapy of pancreatic cancer.Immunotherapy in pancreatic ductal adenocarcinoma: an emerging entity?T-cell Localization, Activation, and Clonal Expansion in Human Pancreatic Ductal Adenocarcinoma.Focused ultrasound for immuno-adjuvant treatment of pancreatic cancer: An emerging clinical paradigm in the era of personalized oncotherapy.Fibroblast drug scavenging increases intratumoural gemcitabine accumulation in murine pancreas cancer.Targeting Pancreatic Cancer Cell Plasticity: The Latest in Therapeutics.Understanding Disease Biology and Informing the Management of Pancreas Cancer With Preclinical Model Systems.The critical roles of activated stellate cells-mediated paracrine signaling, metabolism and onco-immunology in pancreatic ductal adenocarcinoma.Runx3 and Cell Fate Decisions in Pancreas Cancer.Targeting the tumour stroma to improve cancer therapy.Combination Immunotherapy Approaches for Pancreatic Cancer Treatment.Prediction of improved survival in patients with pancreatic cancer via IL-21 enhanced detection of mesothelin epitope-reactive T-cell responses.Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses.Immune therapies in pancreatic ductal adenocarcinoma: Where are we now?Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options
P2860
Q26765438-DF9FCAFD-2137-4756-A00E-54AE67631AF7Q28075540-0EEE2A9B-A59D-4165-BE87-FD2C52482820Q36041701-AFB10CF8-FF22-4487-8553-8B398201BC6FQ36161453-F6A94848-726C-4F57-9F48-489094D48BB0Q36787116-26EDAC6A-FC5F-43E1-B757-FCB1D76AB8BEQ37024754-D70E216F-4CF9-471B-B258-5C68F9CD69A3Q37029731-4C9E259E-6643-4F39-A914-90589659F9F0Q37520133-3BBE07E2-2A4E-48C6-8955-405C1DF0735CQ37554718-93663243-5D7A-402D-99C8-ACD3AB7DEDC3Q38601221-474087D9-ACDC-4395-80E8-BADC6ADAD6AAQ38638035-BE55243D-B516-4138-ABED-2CCDE0C8E519Q38734283-7D600DCE-53AE-4137-BCC4-40644A9E1803Q38845812-63406BB2-C3CD-43EC-93B9-8A5E060E5BBEQ39178061-2F8EE63C-2D2D-4F4D-A001-7E43926A589EQ39202440-47AF02B8-DE82-45FF-816D-F24F33441B30Q39204274-964EF60C-6172-47CD-B785-FE1429E2AE7CQ39262474-AF99802F-4E76-4520-A90F-436C1AF06298Q39268764-31CEFC44-3E25-470C-9206-FE5ADCF051CAQ41514095-9FE6E3D2-3ABD-47E1-9DD5-97DC6760D4EFQ42325128-8A241965-1FF7-429C-979B-5DB28C891FAEQ42570044-A1676A47-9DCF-419C-9279-56A11816570EQ47109220-A62CB7ED-A3D5-4632-BB7A-4CCB780C4387Q47135556-4391C962-7899-404B-AFF1-700F025C6B34Q47248817-E23C402A-81B2-4ECB-A9F7-1FC421C7F8A6Q47568391-A24C85A9-CCCE-42CB-9295-DB9BB70BCBCDQ47726063-642F1F5A-198D-474E-ABD7-FE62B76B4D99Q47726467-7371E5D2-5C40-4D75-BF38-09BB05440B9FQ48873577-6054F9C1-2465-498B-A282-55E2FB13F3C3Q49167162-48415915-0237-4B3B-B169-67C19122956DQ49494945-670246D3-FA1C-4DE9-B8CD-FCCE67DE7A08Q49843616-80E065C6-5340-4568-A1C7-468FA94DBB8CQ51097608-372AD8E2-E56E-4D48-98C0-35FDC55FF356Q52322982-146B3B8F-F9CD-44EE-B32E-C3174A18A743Q53690286-BEE042E1-DB37-4D18-9DAC-D8C5A20852DCQ54941738-1D83EF45-EBDC-449A-ADFF-AFB413013743Q54965295-EE7CFF6D-90BC-4FC3-81B4-76EC9CD2035CQ55240544-D28E077C-2A11-48E6-9DF2-D0D3D2289F43Q56890107-7AC1427F-F0D1-4784-9E81-3A2AC368FFD5
P2860
T Cells Engineered against a Native Antigen Can Surmount Immunologic and Physical Barriers to Treat Pancreatic Ductal Adenocarcinoma.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
T Cells Engineered against a N ...... creatic Ductal Adenocarcinoma.
@ast
T Cells Engineered against a N ...... creatic Ductal Adenocarcinoma.
@en
type
label
T Cells Engineered against a N ...... creatic Ductal Adenocarcinoma.
@ast
T Cells Engineered against a N ...... creatic Ductal Adenocarcinoma.
@en
prefLabel
T Cells Engineered against a N ...... creatic Ductal Adenocarcinoma.
@ast
T Cells Engineered against a N ...... creatic Ductal Adenocarcinoma.
@en
P2093
P2860
P1433
P1476
T Cells Engineered against a N ...... creatic Ductal Adenocarcinoma.
@en
P2093
Ashley M Dotson
Ayaka Hulbert
Carlos Cuevas
Hieu Nguyen
Ingunn M Stromnes
J Scott Brockenbrough
Jennifer L Hotes
Philip D Greenberg
Xiaoxia Tan
P2860
P304
P356
10.1016/J.CCELL.2015.09.022
P577
2015-10-27T00:00:00Z